Renal Impairment and Antibiotic Dosage

Introduction to Renal Impairment and Antibiotics

• Renal impairment affects antibiotic dosage, and guidelines from the Infectious Diseases Society of America and other organizations provide recommendations for dose adjustments in patients with renal impairment 1, 2, 3, 4

Dosing Adjustments for Renal Function

• For patients with normal renal function, no dose adjustment is needed, according to the Infectious Diseases Society of America 1
• For patients with moderate renal impairment, a dose of 250-500 mg every 12 hours is recommended, as suggested by the Infectious Diseases Society of America 1
• For patients with severe renal impairment, a dose of 250-500 mg every 18 hours is recommended, based on guidelines from the Infectious Diseases Society of America 1
• For patients with very severe renal impairment, a dose of 250-500 mg every 24 hours is recommended, according to the Infectious Diseases Society of America 1
• Patients with chronic kidney disease require closer monitoring due to increased risk of recurrence, and those with CrCl ≥50 mL/min require no adjustment, while dose adjustments are necessary for patients with impaired renal function, as recommended by the American College of Critical Care Medicine 5, 6

Considerations for Special Populations

• Patients with multiple medical conditions should have their drug metabolism and clearance assessed, as recommended by the European Association of Urology 7
• Prophylactic regimens may be necessary for patients with recurrent urinary tract infections, as suggested by the American Urological Association 8
• Pregnant patients require admission for initial parenteral therapy, and fluoroquinolones are contraindicated due to teratogenic effects, as recommended by the American College of Physicians and the Infectious Diseases Society of America 5, 4, 2, 9

Treatment of Urinary Tract Infections

• Ciprofloxacin is recommended at a dose of 500-750 mg orally twice daily for 7-14 days for treating urinary tract infections caused by Pseudomonas aeruginosa, with the higher dose of 750 mg twice daily specifically recommended for Pseudomonas infections, as per the European Urology guideline 3
• For non-pregnant females with pyelonephritis and a sulfa allergy, fluoroquinolones (ciprofloxacin 500 mg twice daily or levofloxacin 750 mg once daily for 5-7 days) are the recommended first-line treatment when local resistance rates are <10%, as strongly recommended by the IDSA guidelines 2
• The American College of Physicians recommends a 5-7 day course of fluoroquinolones as first-line therapy for pyelonephritis in females, with clinical cure rates exceeding 93% 5

• Alternative treatment options for patients with contraindications to fluoroquinolones include:

  Antibiotic	Duration
  Cefpodoxime	10-14 days
  Trimethoprim-sulfamethoxazole	14 days
  β-lactams	10-14 days

• For Pseudomonas aeruginosa, ciprofloxacin 750mg twice daily for 14 days is recommended 10
• For Streptococcus pneumoniae, if penicillin-sensitive, amoxicillin 1g three times daily is recommended, and if resistant, levofloxacin 750mg daily is recommended 10
• For Haemophilus influenzae, beta-lactamase negative patients should receive amoxicillin 500mg three times daily, and beta-lactamase positive patients should receive amoxicillin-clavulanate 625mg three times daily 10
• For MSSA, clindamycin 450mg four times daily for 14 days is recommended 11
• For MRSA, doxycycline 100mg twice daily for 14 days is recommended 11
• For mixed infections, amoxicillin-clavulanate 625mg three times daily for 14 days is recommended 11

Pediatric and Pregnancy Considerations

• For children ≥6 months, the American Academy of Pediatrics recommends levofloxacin 8 mg/kg every 12 hours IV or PO (maximum 250 mg/dose) for body weight <50 kg, and 500-750 mg every 24 hours IV or PO for body weight ≥50 kg 12
• For children ≥1 month, the Centers for Disease Control and Prevention recommends ciprofloxacin 10 mg/kg every 8 or 12 hours IV, and 15 mg/kg every 8 or 12 hours PO, with a maximum dose of 400 mg/dose IV and 750 mg/dose PO 13

Monitoring and Follow-up

• Clinical improvement should be seen within 48-72 hours of starting treatment, and follow-up urine culture may be considered in patients with recurrent UTIs to confirm eradication, with reassessment of diagnosis, imaging, and antibiotic choice if no improvement is seen, as recommended by the Infectious Diseases Society of America and the European Urology guideline 2, 3, 4
• Monitoring with CBC and CMP at the end of therapy will help assess for adverse effects and treatment response, which is consistent with the guidelines from the American College of Physicians 5
• Patients with persistent fever after 3-5 days of treatment should undergo reassessment with cultures, as recommended by the Infectious Diseases Society of America 14
• For complicated infections or high-risk patients, an in-person follow-up within 7 days is recommended by the Infectious Diseases Society of America 14

Patient Education and Safety

• Patients should be advised to report all medications they are taking, including over-the-counter drugs, to minimize potential interactions, as emphasized by the American College of Clinical Pharmacy 14
• Healthcare providers should educate patients about potential side effects, such as gastrointestinal effects, central nervous system effects, and skin sensitivity to sunlight, and instruct them on when to seek medical attention, as recommended by the Centers for Disease Control and Prevention 15
• Patients should be instructed to avoid excessive sun exposure and use sunscreen, and to avoid driving or operating machinery if experiencing dizziness, as advised by the American Academy of Family Physicians 16